TAC 278

Known as: 5-Pyrimidinecarboxylic acid, 4-butoxy-5-fluorohexahydro-2,6-dioxo-, ethyl ester, TAC-278 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1982-1982
02419821982

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1983
1983
Transfer of systemically administered fluorinated pyrimidines (Tegafur, TAC-278, HCFU and FD-1) to cerebrospinal fluid was… (More)
Is this relevant?
1982
1982
  • Yuzo Koyama
  • Gan to kagaku ryoho. Cancer & chemotherapy
  • 1982
A new fluorinated pyrimidine, TAC-278, was studied for its safety, anti-tumor activity and pharmacokinetics in patients with… (More)
Is this relevant?
1982
1982
5-fluorouracil analogs investigated in this study include a combination of uracil and Ftorafur (UFT), Ethyl (±)-t-butoxy-5… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1982
1982
  • Gan to kagaku ryoho. Cancer & chemotherapy
  • 1982
A Phase II study of a new fluorinated pyrimidine (TAC-278) was performed in 14 institutions from May 1980 to April 1981. 400-1200… (More)
Is this relevant?
1982
1982
Tumor regression was observed in only one patient. Twelve (33%) of the 36 patients reported adverse effects: gastrointestinal… (More)
Is this relevant?
1982
1982
5-FU analogs being investigated in Japan are; 5-FU, FT, FD-1, HCFU, UFT, TAC-278, 5'-DFUR, FF-705, and TK-117. They exert… (More)
Is this relevant?